1h Free Analyst Time
Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 46 molecules. Out of which approximately 38 molecules are developed by companies and remaining by the universities/institutes. The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 8, 3, 14 and 8 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Metabolic Disorders, Cardiovascular, Ophthalmology, Gastrointestinal, Immunology, Genetic Disorders, Oncology and Respiratory which include indications Neuropathic Pain (Neuralgia), Pain, Osteoarthritis Pain, Cancer Pain, Diabetic Peripheral Neuropathy, Ocular Pain (Eye Pain), Postherpetic Neuralgia, Pruritus, Inflammatory Pain, Keratoconjunctivitis Sicca (Dry Eye), Visceral Pain, Alzheimer's Disease, Atopic Dermatitis (Atopic Eczema), Autoimmune Hepatitis, Blepharospasm, Breast Cancer, Cardiomegaly, Cardiovascular Disease, Chronic Heart Failure, Cluster Headache Syndrome (Cluster Headache), Congestive Heart Failure (Heart Failure), Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Hypertension, Infantile Spasm (West Syndrome), Inflammation, Insomnia, Irritable Bowel Syndrome, Ischemia Reperfusion Injury, Myocardial Infarction, Non-Alcoholic Steatohepatitis (NASH), Ocular Hypertension, Ocular Inflammation, Open-Angle Glaucoma, Parkinson's Disease, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Post-Operative Pain, Prostate Cancer, Psoriasis, Radiculopathy, Schizophrenia, Skin Inflammation, Squamous Cell Carcinoma, Tremor, Tuberous Sclerosis and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
- Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indications, H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1)
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Products under Development by Companies, H1 2020 (Contd..3), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by AlzeCure Pharma AB, H1 2020
- Pipeline by Amorepacific Corp, H1 2020
- Pipeline by AntalGenics SL, H1 2020
- Pipeline by Astellas Pharma Inc, H1 2020
- Pipeline by Bsense Bio Therapeutics Ltd, H1 2020
- Pipeline by Centrexion Therapeutics Corp, H1 2020
- Pipeline by Cmxtwenty, H1 2020
- Pipeline by Concentric Analgesics Inc, H1 2020
- Pipeline by GB Sciences Inc, H1 2020
- Pipeline by GBSciences Inc, H1 2020
- Pipeline by Grunenthal GmbH, H1 2020
- Pipeline by GW Pharmaceuticals Plc, H1 2020
- Pipeline by Interventional Analgesix Inc, H1 2020
- Pipeline by Ion Channel Pharmacology LLC, H1 2020
- Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
- Pipeline by Medifron DBT Co Ltd, H1 2020
- Pipeline by Mestex AG, H1 2020
- Pipeline by Neurim Pharmaceuticals Ltd, H1 2020
- Pipeline by Novartis AG, H1 2020
- Pipeline by Oblique Therapeutics AB, H1 2020
- Pipeline by Pila Pharma AB, H1 2020
- Pipeline by Revive Therapeutics Ltd, H1 2020
- Pipeline by Scopus BioPharma Inc, H1 2020
- Pipeline by Serentrix LLC, H1 2020
- Pipeline by Sorrento Therapeutics Inc, H1 2020
- Pipeline by Sylentis SAU, H1 2020
- Pipeline by Vitality Biopharma Inc, H1 2020
- Pipeline by Winston Pharmaceuticals Inc, H1 2020
- Pipeline by Young BioPharma LLC, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Dormant Products, H1 2020 (Contd..2), H1 2020
- Dormant Products, H1 2020 (Contd..3), H1 2020
- Dormant Products, H1 2020 (Contd..4), H1 2020
- Dormant Products, H1 2020 (Contd..5), H1 2020
- Dormant Products, H1 2020 (Contd..6), H1 2020
- Discontinued Products, H1 2020
- Discontinued Products, H1 2020 (Contd..1), H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Mechanism of Actions, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AlzeCure Pharma AB
- Amorepacific Corp
- AntalGenics SL
- Astellas Pharma Inc
- Bsense Bio Therapeutics Ltd
- Centrexion Therapeutics Corp
- Cmxtwenty
- Concentric Analgesics Inc
- GB Sciences Inc
- GBSciences Inc
- Grunenthal GmbH
- GW Pharmaceuticals Plc
- Interventional Analgesix Inc
- Ion Channel Pharmacology LLC
- Jeil Pharmaceutical Co Ltd
- Medifron DBT Co Ltd
- Mestex AG
- Neurim Pharmaceuticals Ltd
- Novartis AG
- Oblique Therapeutics AB
- Pila Pharma AB
- Revive Therapeutics Ltd
- Scopus BioPharma Inc
- Serentrix LLC
- Sorrento Therapeutics Inc
- Sylentis SAU
- Vitality Biopharma Inc
- Winston Pharmaceuticals Inc
- Young BioPharma LLC
